Literature DB >> 20501944

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

Jo Eyles1, Anne-Laure Puaux, Xiaojie Wang, Benjamin Toh, Celine Prakash, Michelle Hong, Tze Guan Tan, Lin Zheng, Lai Chun Ong, Yi Jin, Masashi Kato, Armelle Prévost-Blondel, Pierce Chow, Henry Yang, Jean-Pierre Abastado.   

Abstract

Although metastasis is the leading cause of cancer-related death, it is not clear why some patients with localized cancer develop metastatic disease after complete resection of their primary tumor. Such relapses have been attributed to tumor cells that disseminate early and remain dormant for prolonged periods of time; however, little is known about the control of these disseminated tumor cells. Here, we have used a spontaneous mouse model of melanoma to investigate tumor cell dissemination and immune control of metastatic outgrowth. Tumor cells were found to disseminate throughout the body early in development of the primary tumor, even before it became clinically detectable. The disseminated tumor cells remained dormant for varying periods of time depending on the tissue, resulting in staggered metastatic outgrowth. Dormancy in the lung was associated with reduced proliferation of the disseminated tumor cells relative to the primary tumor. This was mediated, at least in part, by cytostatic CD8+ T cells, since depletion of these cells resulted in faster outgrowth of visceral metastases. Our findings predict that immune responses favoring dormancy of disseminated tumor cells, which we propose to be the seed of subsequent macroscopic metastases, are essential for prolonging the survival of early stage cancer patients and suggest that therapeutic strategies designed to reinforce such immune responses may produce marked benefits in these patients.

Entities:  

Mesh:

Year:  2010        PMID: 20501944      PMCID: PMC2877955          DOI: 10.1172/JCI42002

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

1.  A survival benefit from axillary dissection: was Halsted correct?

Authors:  M Morrow
Journal:  Ann Surg Oncol       Date:  1999 Jan-Feb       Impact factor: 5.344

2.  Optimal genotype determination in highly multiplexed SNP data.

Authors:  Martin Moorhead; Paul Hardenbol; Farooq Siddiqui; Matthew Falkowski; Carsten Bruckner; James Ireland; Hywel B Jones; Maneesh Jain; Thomas D Willis; Malek Faham
Journal:  Eur J Hum Genet       Date:  2006-02       Impact factor: 4.246

3.  Is cancer a disease of self-seeding?

Authors:  Larry Norton; Joan Massagué
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

4.  Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.

Authors:  Larry Norton
Journal:  Oncologist       Date:  2005 Jun-Jul

5.  Clonal history of papillomavirus-induced dysplasia in the female lower genital tract.

Authors:  Svetlana Vinokurova; Nicolas Wentzensen; Jens Einenkel; Ruediger Klaes; Corina Ziegert; Peter Melsheimer; Heike Sartor; Lars-Christian Horn; Michael Höckel; Magnus von Knebel Doeberitz
Journal:  J Natl Cancer Inst       Date:  2005-12-21       Impact factor: 13.506

6.  The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis.

Authors:  Simone Mocellin; Dave Hoon; Alessandro Ambrosi; Donato Nitti; Carlo Riccardo Rossi
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

7.  Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior?

Authors:  S Staibano; M Mascolo; F Tranfa; G Salvatore; C Mignogna; P Bufo; L Nugnes; G Bonavolontà; G De Rosa
Journal:  Int J Immunopathol Pharmacol       Date:  2006 Jan-Mar       Impact factor: 3.219

8.  CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.

Authors:  Irene M Mullins; Craig L Slingluff; Jae K Lee; Courtney F Garbee; Jianfen Shu; Sara G Anderson; Melanie E Mayer; William A Knaus; David W Mullins
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

9.  Circulating tumor cells in patients with breast cancer dormancy.

Authors:  Songdong Meng; Debasish Tripathy; Eugene P Frenkel; Sanjay Shete; Elizabeth Z Naftalis; James F Huth; Peter D Beitsch; Marilyn Leitch; Susan Hoover; David Euhus; Barbara Haley; Larry Morrison; Timothy P Fleming; Dorothee Herlyn; Leon W M M Terstappen; Tanja Fehm; Thomas F Tucker; Nancy Lane; Jianqiang Wang; Jonathan W Uhr
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

10.  The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.

Authors:  Franca Piras; Romano Colombari; Luigi Minerba; Daniela Murtas; Carlo Floris; Cristina Maxia; Arianna Corbu; M Teresa Perra; Paola Sirigu
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

View more
  227 in total

1.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 2.  Immune predictors of cancer progression.

Authors:  Benjamin Toh; Valerie Chew; Xilei Dai; Karen Khoo; Muly Tham; Lu-En Wai; Sandra Hubert; Sumathy Velumani; Liang Zhi; Caleb Huang; Jean-Pierre Abastado
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Early tumor dissemination, but late metastasis: insights into tumor dormancy.

Authors:  Martin Röcken
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

4.  Tumour immunology: Run and hide.

Authors:  Olive Leavy
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

5.  Don't let sleeping cells lie.

Authors:  Teresa Villanueva
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

Review 6.  Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.

Authors:  Peter J Chockley; Venkateshwar G Keshamouni
Journal:  J Immunol       Date:  2016-08-01       Impact factor: 5.422

Review 7.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

8.  Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence.

Authors:  David D Tran; Callie Ann S Corsa; Hirak Biswas; Rebecca L Aft; Gregory D Longmore
Journal:  Mol Cancer Res       Date:  2011-10-17       Impact factor: 5.852

9.  IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.

Authors:  Lloyd Bod; Renée Lengagne; Ludovic Wrobel; Jan Philipp Ramspott; Masashi Kato; Marie-Françoise Avril; Flavia Castellano; Valérie Molinier-Frenkel; Armelle Prévost-Blondel
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

10.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.